RxDoctor Payments Data

Juliet Yirerong, MD

Cardiovascular Disease · Bridgeport, CTNPI 1043663826

Payments from drug & device makers

$9,407in general payments, 2019–2025

Across 329 payments — averaging $28.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AstraZeneca$686
  • Novo Nordisk$630
  • Merck$487
  • Boehringer Ingelheim$472
  • Pfizer$462
  • plus $5K from 36 others

What the payments were for

  • Travel & lodging$1,33014%
  • Food & beverage$8,06386%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,407 in reported general payments places this provider in the 75th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$124,428
Medicare patients
443
Services billed
1,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$65,365
EntrestoSacubitril/Valsartan62$52,883
JardianceEmpagliflozin49$52,499
XareltoRivaroxaban13$21,947
NexlizetBempedoic Acid/Ezetimibe14$10,255
VascepaIcosapent Ethyl16$8,295
Metoprolol Succinate143$1,309
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$1,154
Valsartan19$1,085
Atorvastatin Calcium166$914
Rosuvastatin Calcium93$708
Carvedilol127$678
Bumetanide12$359
Furosemide63$292
Amlodipine Besylate81$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$462$65,36566 claims
NovartisEntresto$406$52,88362 claims
Boehringer IngelheimJardiance$472$52,49949 claims
Johnson & JohnsonXarelto$345$21,94713 claims
Esperion Therapeutics, Inc.Nexlizet$179$10,25514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →